- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05140070
Fruit and Vegetable Products Enriched With Fibre From Potato Starch With Prebiotic Properties for Children and Youth
Development and Implementation of an Innovative Technology for the Production New Generation Fruit and Vegetable Products Enriched With Dietary Fibre Preparation From Potato Starch With Prebiotic Properties for Children and Youth
The main goal of the project is to test fruit and vegetable mousse, with the addition of a fiber preparation made of potato starch with prebiotic properties, on selected clinical, metabolic and immunological parameters in overweight and obese children.
The study will be performed in a group of 80 to 100 children aged 6 to 10 years (pre-pubertal age), using a double-blind procedure. Children will be randomly assigned into two groups, i.e. the intervention group (they will receive a vegetable and fruit mousse with the addition of potato starch fiber preparation with prebiotic properties) and the control group (they will receive an identical preparation in their diet, but without the addition of potato starch fiber preparation).
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Purpose and nature of the study:
The study financed by the National Center for Research and Development is aimed at examining the vegetable and fruit mousse with the addition of a potato starch fiber preparation with prebiotic properties, in terms of preventing overweight and obesity in children and limiting the occurrence of metabolic disorders secondary to obesity.
Description of the procedures Children participating in the study will consume a daily fruit and vegetable mousse with or without the addition (control group) of a fiber-based potato starch preparation with prebiotic properties. Random selection will decide whether child will consume vegetable and fruit mousse with the addition of a fiber-based potato starch preparation with prebiotic properties. The study will be double blinded: neither parent and child, nor the attending physician will know whether the consumed mousse contains a fiber preparation. This method of conducting the study (random selection to the study group and control group and the so-called study blind) aims to eliminate the attitude of both the study participant and the observer to the therapy, which could affect the final assessment.
Children will take the mousse every day for six months (6 months). In order to evaluate the effect of fruit and vegetable mousse with the addition of a fiber preparation made of potato starch with prebiotic properties, the following tests will be performed: measurements of height, weight and, based on this measurements body mass index (BMI) will be calculated, waist circumference and blood pressure, bioimpedance test to assess the content of adipose and muscle tissue in the body, ultrasound of the carotid vessels and the liver, the speed of the pulse wave using the oscillometric method, the elastographic examination with a fibroscan, the examination of the composition of the intestinal flora in a stool sample, and a venous blood sample (7-10 ml volume) will be taken to evaluate lipid, carbohydrate metabolism, liver function, adipose tissue function, antioxidant status, and immune response parameters. The mentioned tests will be performed three times during the observation, i.e. at the time of enrollment in the study, after 6 months of taking the fruit and vegetable mousse and 3 months after the end of the vegetable and fruit mousse. In connection with participation in the study, the Child and Parents will be provided with dietary and physical activity advice as well as psychologist's advice on the day of enrollment in the study and at 3-month intervals up to 9 months from the start of participation in the study. Additionally, 3 months after starting taking the fruit and vegetable mousse, anthropometric and blood pressure measurements will be performed. During the participation in the study possible side effects will be registered.
A questionnaire containing questions about the child's date of birth, questions about the child's general health and taking medications, about the socio-demographic situation of the family, and food frequency questions will be completed.
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Piotr Socha, MD, PhD
- Número de teléfono: +48 501065154
- Correo electrónico: p.socha@ipczd.pl
Copia de seguridad de contactos de estudio
- Nombre: Zbigniew Kułaga, MD, PhD
- Número de teléfono: +48 603547517
- Correo electrónico: zakulaga@gmail.com
Ubicaciones de estudio
-
-
-
Warszawa, Polonia, 03-984
- Reclutamiento
- The Childen's Memorial Health Institute
-
Contacto:
- Piotr Socha, Professor, MD, PhD
- Número de teléfono: +48 501 065 154
- Correo electrónico: zakulaga@gmail.com
-
Contacto:
- Zbigniew Zbigniew, MD, PhD
- Número de teléfono: 603547517
- Correo electrónico: zakulaga@gmail.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- overweight or obesity according to World Health Organization (WHO) definition
- in 20 patients additionally to overweight or obesity also increase blood pressure
- in 20 patients additionally to overweight or obesity also liver steatosis
- willingness to participate
Exclusion Criteria:
- allergy to mousse components
- malabsorption syndrome
- organ failure
- food neophobia
- other diseases or health problems which may interfere with study procedures or safety.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Intervention
Mousse with prebiotic
|
All children in the intervention group will consume on daily basis vegetable and fruit mousse enriched with a fiber preparation from potato starch with prebiotic properties for six months
All children in the study will obtain 4 dietary and physical activity advice during the course of the study
|
|
Comparador activo: Control
Mousse without prebiotic
|
All children in the study will obtain 4 dietary and physical activity advice during the course of the study
All children in the control group will consume on daily basis vegetable and fruit mousse for six months
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
BMI z-score change
Periodo de tiempo: 6 to 9 months
|
Change in age and sex standardized BMI z-scores
|
6 to 9 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Bioimpedance
Periodo de tiempo: 6 to 9 months
|
Change in body composition on bioimpedance (fat-body-mass %)
|
6 to 9 months
|
|
Waist
Periodo de tiempo: 6 to 9 months
|
Change in waist z-score (cm)
|
6 to 9 months
|
|
Gut microbiota
Periodo de tiempo: 6 to 9 months
|
change in microbiome composition
|
6 to 9 months
|
|
Triglyceride
Periodo de tiempo: 6 to 9 months
|
change in triglyceride-parameter of lipid metabolism (mg%)
|
6 to 9 months
|
|
Cholesterol
Periodo de tiempo: 6 to 9 months
|
change in cholesterol-parameter of lipid metabolism (mg%)
|
6 to 9 months
|
|
Low-density lipoprotein (LDL)
Periodo de tiempo: 6 to 9 months
|
change in Low-density lipoprotein (LDL)-parameter of lipid metabolism (mg%)
|
6 to 9 months
|
|
high-density lipoprotein (HDL)
Periodo de tiempo: 6 to 9 months
|
change in high-density lipoprotein (HDL)-parameter of lipid metabolism (mg%)
|
6 to 9 months
|
|
very low-density lipoprotein (VLDL)
Periodo de tiempo: 6 to 9 months
|
change in very low-density lipoprotein (VLDL)-parameter of lipid metabolism (mg%)
|
6 to 9 months
|
|
apolipoprotein
Periodo de tiempo: 6 to 9 months
|
change in apolipoprotein-parameter of lipid metabolism (mg%)
|
6 to 9 months
|
|
uric acid
Periodo de tiempo: 6 to 9 months
|
change in uric acid (mg%)
|
6 to 9 months
|
|
leptin
Periodo de tiempo: 6 to 9 months
|
change in leptin (ng/mL)
|
6 to 9 months
|
|
adiponectin
Periodo de tiempo: 6 to 9 months
|
change in adiponectin (ng/mL)
|
6 to 9 months
|
|
glucose, serum
Periodo de tiempo: 6 to 9 months
|
change in glucose (mg%)
|
6 to 9 months
|
|
insulin, serum
Periodo de tiempo: 6 to 9 months
|
change in insulin (mcIU/mL)
|
6 to 9 months
|
|
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Periodo de tiempo: 6 to 9 months
|
change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), score, normal range<2,5
|
6 to 9 months
|
|
Glutathione (GSH)
Periodo de tiempo: 6 to 9 months
|
change in Glutathione (GSH) (g Hgb/mcL)
|
6 to 9 months
|
|
glutathione peroxidase (GPx)
Periodo de tiempo: 6 to 9 months
|
change in glutathione peroxidase (GPx) (mg/dL)
|
6 to 9 months
|
|
total antioxidant status (TAS)
Periodo de tiempo: 6 to 9 months
|
change in total antioxidant status (TAS) (mcmol/L)
|
6 to 9 months
|
|
tumor necrosis factor α (TNF-alfa)
Periodo de tiempo: 6 months
|
change in tumor necrosis factor α (TNF-alfa) (ng/mL)
|
6 months
|
|
interleukin 6 (IL-6)
Periodo de tiempo: 6 months
|
change in interleukin 6 (IL-6) (ng/mL)
|
6 months
|
|
Monocyte Chemoattractant Protein-1 (MCP-1)
Periodo de tiempo: 6 months
|
change in Monocyte Chemoattractant Protein-1 (MCP-1) (ng/mL)
|
6 months
|
|
Macrophage Inflammatory Protein-1 (MIP-1) alfa and beta
Periodo de tiempo: 6 months
|
change in Macrophage Inflammatory Protein-1 (MIP-1) alfa and beta (ng/mL)
|
6 months
|
|
Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted (RANTES)
Periodo de tiempo: 6 months
|
change in Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted (RANTES) (ng/mL)
|
6 months
|
|
lymphocyte T
Periodo de tiempo: 6 months
|
change in lymphocyte T (%)
|
6 months
|
Colaboradores e Investigadores
Publicaciones y enlaces útiles
Publicaciones Generales
- Barczynska R, Kapusniak J, Litwin M, Slizewska K, Szalecki M. Dextrins from Maize Starch as Substances Activating the Growth of Bacteroidetes and Actinobacteria Simultaneously Inhibiting the Growth of Firmicutes, Responsible for the Occurrence of Obesity. Plant Foods Hum Nutr. 2016 Jun;71(2):190-6. doi: 10.1007/s11130-016-0542-9.
- Barczynska R, Bandurska K, Slizewska K, Litwin M, Szalecki M, Libudzisz Z, Kapusniak J. Intestinal Microbiota, Obesity and Prebiotics. Pol J Microbiol. 2015;64(2):93-100.
- Barczynska R, Slizewska K, Litwin M, Szalecki M, Kapusniak J. Effects of dietary fiber preparations made from maize starch on the growth and activity of selected bacteria from the Firmicutes, Bacteroidetes, and Actinobacteria phyla in fecal samples from obese children. Acta Biochim Pol. 2016;63(2):261-6. doi: 10.18388/abp.2015_1068. Epub 2016 Feb 29.
- Litwin M, Sladowska J, Antoniewicz J, Niemirska A, Wierzbicka A, Daszkowska J, Wawer ZT, Janas R, Grenda R. Metabolic abnormalities, insulin resistance, and metabolic syndrome in children with primary hypertension. Am J Hypertens. 2007 Aug;20(8):875-82. doi: 10.1016/j.amjhyper.2007.03.005.
- Litwin M, Michalkiewicz J, Trojanek J, Niemirska A, Wierzbicka A, Szalecki M. Altered genes profile of renin-angiotensin system, immune system, and adipokines receptors in leukocytes of children with primary hypertension. Hypertension. 2013 Feb;61(2):431-6. doi: 10.1161/HYPERTENSIONAHA.111.00181. Epub 2012 Dec 24.
- Pinket AS, Van Lippevelde W, De Bourdeaudhuij I, Deforche B, Cardon G, Androutsos O, Koletzko B, Moreno LA, Socha P, Iotova V, Manios Y, De Craemer M; ToyBox-Study Group. Effect and Process Evaluation of a Cluster Randomized Control Trial on Water Intake and Beverage Consumption in Preschoolers from Six European Countries: The ToyBox-Study. PLoS One. 2016 Apr 11;11(4):e0152928. doi: 10.1371/journal.pone.0152928. eCollection 2016.
- Socha P, Grote V, Gruszfeld D, Janas R, Demmelmair H, Closa-Monasterolo R, Subias JE, Scaglioni S, Verduci E, Dain E, Langhendries JP, Perrin E, Koletzko B; European Childhood Obesity Trial Study Group. Milk protein intake, the metabolic-endocrine response, and growth in infancy: data from a randomized clinical trial. Am J Clin Nutr. 2011 Dec;94(6 Suppl):1776S-1784S. doi: 10.3945/ajcn.110.000596. Epub 2011 Aug 17.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- PreSTFibre4kids
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Marco de tiempo para compartir IPD
Criterios de acceso compartido de IPD
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .